Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: Beam Therapeutics has reported its financial results for the second quarter of 2026, highlighting a successful dosing of the first patient in the global pivotal cohort of the BEAM-302 trial for Alpha-1 Antitrypsin Deficiency. Additionally, the updated Phase 1/2 clinical data has been selected for a late-breaking oral presentation at the European Respiratory Society Congress. The company also completed dosing for all patients in the BEACON trial of Risto-cel in Sickle Cell Disease.
Market Sentiment Analysis
POSITIVE FACTORS
First patient dosed in pivotal BEAM-302 trial.
Positive financial results reported for Q2 2026.
Updated data selected for presentation at ERS Congress.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~27 mo
Minimal dilution risk
Lead asset
BEAM-302
Phase 1 · Alpha 1-Antitrypsin Deficiency
Full Press Release Details
Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients in Phase 1/2 BEACON Trial of Risto-cel in Sickle Cell Disease; U.S.
Frequently Asked Questions
What were Beam Therapeutics' Q2 2026 financial results?
Beam Therapeutics reported positive financial results for the second quarter of 2026.
What is the BEAM-302 trial about?
The BEAM-302 trial focuses on treating Alpha-1 Antitrypsin Deficiency.
Who was the first patient dosed in the BEAM-302 trial?
The first patient in the global pivotal cohort of the BEAM-302 trial has been dosed.
Where will the updated BEAM-302 data be presented?
The updated data will be presented at the European Respiratory Society Congress.
What is the BEACON trial?
The BEACON trial involves Risto-cel for treating Sickle Cell Disease.